Hyperperfusion Syndrome Following Tissue Plasminogen Activator Administration: A Case Report with Radiological Evidence [PDF]
Journal of the Korean Society of RadiologyCerebral hyperperfusion syndrome is a rare complication that can occur following carotid artery revascularization procedures in patients with chronic carotid artery stenosis.
Nam Hee Koh +4 more
doaj +2 more sources
Incidence of Hemorrhagic Complications among Patients Treated with Thrombolytic in Erbil City, Iraq [PDF]
Al-Anbar Medical Journal, 2020 Background: Recombinant tissue-type plasminogen activator is an option of treatment for suspected occlusive vascular thrombi and its sequel (transmural myocardial infarction, pulmonary embolism, and ischemic stroke). The most important concern associated
Ahmed F. Hammad +2 more
doaj +1 more source
Histone deacetylase inhibitor treatment increases coronary t-PA release in a porcine ischemia model. [PDF]
PLoS ONE, 2014 BACKGROUND: The expression of the tissue plasminogen activator gene can be affected by histone deacetylation inhibition and thus appears to be under epigenetic control.
Kristina Svennerholm +6 more
doaj +1 more source
Intravenous tissue plasminogen activator in functional stroke mimics [PDF]
Advances in Psychiatry and NeurologyMagdalena M. Kowalska +2 more
doaj +2 more sources
The Neurotoxicity of Tissue Plasminogen Activator? [PDF]
Journal of Cerebral Blood Flow & Metabolism, 2004 Tissue plasminogen activator (tPA), a fibrin specific activator for the conversion of plasminogen to plasmin, stimulates thrombolysis and rescues ischemic brain by restoring blood flow. However, emerging data suggests that under some conditions, both tPA and plasmin, which are broad spectrum protease enzymes, are potentially neurotoxic if they reach ...
Kaur, J +4 more
openaire +4 more sources
Tissue Plasminogen Activator [PDF]
New England Journal of Medicine, 1989 Coronary thrombolysis has been proved to be beneficial in the treatment of myocardial infarction. Much attention has been focused on tissue-type plasminogen activator (t-PA) as a fibrinolytic agent. This article will discuss the unique properties of t-PA and the role of the critical care nurse in providing the safe delivery of t-PA.
openaire +5 more sources
Peripheral embolization following thrombolytic therapy for acute ischemic stroke—a case report
The Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2020 Background Intravenous recombinant tissue plasminogen activator is the only golden approved medical therapy for acute ischemic stroke, guidelines for its injection relay on reducing or preventing associated hemorrhage as a side effect, yet hemorrhage is ...
Tamer Roushdy +5 more
doaj +1 more source
Scientific Reports, 2021 Patients with coronavirus disease-19 (COVID-19) are at high risk for thrombotic arterial and venous occlusions. However, bleeding complications have also been observed in some patients.
Yu Zuo +9 more
doaj +1 more source
Fibrinolysis regulation by platelets retaining plasminogen and tissue-type plasminogen activator on their surface [PDF]
The Ukrainian Biochemical Journal, 2019 Platelets play a key role in hemostasis as cofactors of thrombin generation, fibrin polymerization centers, and initiators of clot retraction, while their ability to modulate clot dissolution remains less understood.
T. Grinenko +4 more
doaj +1 more source
Tissue plasminogen activator and urokinase plasminogen activator in human epileptogenic pathologies [PDF]
Neuroscience, 2010 A growing body of evidence demonstrates the involvement of plasminogen activators (PAs) in a number of physiologic and pathologic events in the CNS. Induction of both tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA) has been observed in different experimental models of epilepsy and tPA has been implicated in the mechanisms ...
A. M. Iyer +12 more
openaire +8 more sources